Current status and perspective of angiogenesis and antivascular therapeutic strategy: non-small cell lung cancer
- 20 April 2006
- journal article
- review article
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 11 (2), 73-81
- https://doi.org/10.1007/s10147-006-0568-3
Abstract
No abstract availableKeywords
This publication has 56 references indexed in Scilit:
- Lung Cancer Highlights from ASCO 2005The Oncologist, 2006
- Antitumor Vascular Strategy for Controlling Experimental Metastatic Spread of Human Small-Cell Lung Cancer Cells with ZD6474 in Natural Killer Cell–Depleted Severe Combined Immunodeficient MiceClinical Cancer Research, 2005
- Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)The Lancet, 2005
- Angiogenesis and Lung Cancer: Prognostic and Therapeutic ImplicationsJournal of Clinical Oncology, 2005
- Epidermal Growth Factor Receptor Gene and Protein and Gefitinib Sensitivity in Non–Small-Cell Lung CancerJNCI Journal of the National Cancer Institute, 2005
- Sensitization of Tumor-Associated Endothelial Cell Apoptosis by the Novel Vascular-Targeting Agent ZD6126 in Combination with CisplatinClinical Cancer Research, 2004
- Akt Phosphorylation and Gefitinib Efficacy in Patients With Advanced Non-Small-Cell Lung CancerJNCI Journal of the National Cancer Institute, 2004
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- Tumor angiogenesis and accessibility: Role of vascular endothelial growth factorSeminars in Oncology, 2002